FDA Approves BridgeBio's Heart Drug, Sparking Competition with Pfizer
TL;DR Summary
The FDA has approved BridgeBio's new drug, Attruby, for treating transthyretin amyloid cardiomyopathy (ATTR-CM), marking the first new treatment for this heart condition in over five years. ATTR-CM, which affects over 400,000 people globally, is caused by genetic mutations or aging, leading to amyloid deposits in the heart that impair its function. This approval represents BridgeBio's first major commercial product.
- BridgeBio wins FDA approval for heart disease drug STAT
- FDA approves BridgeBio’s heart disease drug, setting up competition with Pfizer, Alnylam Endpoints News
- Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients Yahoo Finance
- BridgeBio's Attruby Wins FDA Approval: 42% Reduction in ATTR-CM Mortality & Hospitalizations | BBIO Stock News StockTitan
- BridgeBio heart drug approved by FDA, setting up battle with Pfizer BioPharma Dive
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
71%
209 → 60 words
Want the full story? Read the original article
Read on STAT